Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) (SGN+Benda)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01657331
Recruitment Status : Active, not recruiting
First Posted : August 6, 2012
Last Update Posted : April 9, 2018
Information provided by (Responsible Party):
Owen A. O'Connor, Columbia University